BRIEF published on 08/30/2024 at 07:05, 2 months 22 days ago Vita 34 AG Sustains Growth in H1 2024, Strongly Boosts Operating Cash Flow Revenue Growth Operating Cash Flow Vita 34 AG EBITDA Increase H1 2024 Results
PRESS RELEASE published on 08/30/2024 at 07:00, 2 months 22 days ago Vita 34 continues positive trend in the first half of 2024 and once again significantly increases operating cash flow Vita 34 AG reports positive first half of 2024 with revenue growth and increased operating cash flow. EBITDA up by 76.4%. Full-year outlook confirmed EBITDA Revenue Growth Operating Cash Flow Vita 34 AG First Half Results
BRIEF published on 08/09/2024 at 17:09, 3 months 11 days ago Subsidiaries of Vita 34 Reach Agreement with US Licensor Vita 34 FamiCordTx PBKM CAR-T Technology Biotechnology Agreement
PRESS RELEASE published on 08/09/2024 at 17:04, 3 months 11 days ago EQS-Adhoc: Subsidiaries of Vita 34 reach agreement with US licensor Vita 34 AG subsidiaries reach agreement with US licensor on CAR-T technology, settling previous lawsuit and securing new know-how licensing agreement Vita 34 AG Agreement Subsidiaries CAR-T Technology US Licensor
BRIEF published on 08/01/2024 at 12:44, 3 months 19 days ago Thomas Pfaadt Appointed as New Chief Financial Officer of Vita 34 AG Chief Financial Officer Finance Management Board Vita 34 AG Thomas Pfaadt
PRESS RELEASE published on 08/01/2024 at 12:39, 3 months 19 days ago Thomas Pfaadt appointed as new Chief Financial Officer of Vita 34 AG Thomas Pfaadt appointed as new CFO of Vita 34 AG, bringing 20+ years of experience. Management Board complete. Vita 34, leading cell bank in Europe, focusing on cell banking and investments in therapies CFO Vita 34 AG Investments Thomas Pfaadt Cell Banking
BRIEF published on 05/31/2024 at 08:38, 5 months 21 days ago Vita 34 Reports Significant Increases in Earnings and Cash Flow EBITDA Revenue Growth Operating Cash Flow Q1 2024 Earnings Vita 34
PRESS RELEASE published on 05/31/2024 at 08:33, 5 months 21 days ago Vita 34 significantly increases earnings and operating cash flow in the first quarter Vita 34 AG reports a significant increase in earnings and operating cash flow in the first quarter of 2024, with revenues up by 3.6% to EUR 18.6 million. EBITDA exceeds EUR 1.5 million Revenues Business Development Earnings Operating Cash Flow Vita 34 AG
BRIEF published on 04/30/2024 at 22:56, 6 months 20 days ago Vita 34 Sees Financial Growth and Improvement in 2023 Investment Strategies 2024 Outlook Vita 34 AG Financial Growth Increase In EBITDA
PRESS RELEASE published on 04/30/2024 at 22:51, 6 months 20 days ago Vita 34 returns to growth path in 2023 Vita 34 AG reports 11.8% revenue growth to EUR 77.1 million in 2023 despite challenging environment. EBITDA significantly improved to EUR 5.6 million EBITDA Revenue Growth Business Development Vita 34 AG Cell Bank
Published on 11/21/2024 at 10:03, 45 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 48 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 48 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 13 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 23 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 10:30, 18 minutes ago MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 43 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 46 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 48 minutes ago Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 48 minutes ago Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 06:58, 3 hours 50 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 28 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 17 hours 3 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 17 hours 3 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 3 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
